Precision Biosciences Inc

NASDAQ:DTIL   3:59:59 PM EDT
8.49
-0.50 (-5.56%)
Products, Strategic Combinations, Regulatory

Precision Biosciences Says Co & Springworks Therapeutics Announced They Have Entered Into A Clinical Trial Collaboration Agreement

Published: 09/21/2020 11:35 GMT
Precision Biosciences Inc (DTIL) - Precision Biosciences - Co & Springworks Therapeutics Announced They Have Entered Into a Clinical Trial Collaboration Agreement.
Precision - per Agreement, Pbcar269a to Be Evaluated With Nirogacestat, Springworks' Investigational Gsi, in Relapsed/refractory Multiple Myeloma Patients.
Precision Biosciences - Under Terms of Agreement, Co Will Assume All Development Costs of Expanded Phase 1/2a Study of Pbcar269a.
Precision - Co & Springworks Will Form Joint Development Committee to Oversee Phase 1/2a Study of Pbcar269a Which is Expected to Commence in H1 2021.